RT期刊文章SR电子T1尼古丁的治疗轻度认知障碍摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 91 OP 101 10.1212 /首页 WNL。0 b013e31823efcbb VO 78是2 A1 p·纽豪斯A1 K。Kellar A1 p·爱森A1 h .白色A1 K。Wesnes A1大肠Coderre A1。普法夫A1 h·威尔金斯A1 d·霍华德A1 E.D.莱文年2012 UL //www.ez-admanager.com/conten首页t/78/2/91.abstract AB目的:初步评估经皮的尼古丁疗法的安全性和有效性认知表现和临床学科地位与轻度认知障碍(MCI)。方法:不吸烟被遗忘MCI被随机分配到皮肤尼古丁(每天15毫克或安慰剂)6个月。主要的结果变量是注意力改善评估与康纳斯连续性能测试(CPT),以临床临床改善全球印象,安全措施。二次措施包括计算机认知测试和病人和观察者的评级。结果:74名受试者中,39随机安慰剂尼古丁和35。67例(34尼古丁,33安慰剂)完成。主要的认知结果测量(CPT)显示显著身上观察到尼古丁诱导下。改善 There was no statistically significant effect on clinician-rated global improvement. The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. Safety and tolerability for transdermal nicotine were excellent. Conclusion: This study demonstrated that transdermal nicotine can be safely administered to nonsmoking subjects with MCI over 6 months with improvement in primary and secondary cognitive measures of attention, memory, and mental processing, but not in ratings of clinician-rated global impression. We conclude that this initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies. Classification of evidence: This study provides Class I evidence that 6 months of transdermal nicotine (15 mg/day) improves cognitive test performance, but not clinical global impression of change, in nonsmoking subjects with amnestic MCI. AD=Alzheimer disease; AE=adverse event; BMI=body mass index; CDR=Clinical Dementia Rating; CGIC=Clinical Global Impression of Change; CPT=Continuous Performance Test; CRT=Choice Reaction Time; MCI=mild cognitive impairment; OASR=Older Adult Self Report; OABCL=Older Adult Behavior Checklist; RT=reaction time

map